

ASX Announcement

Orthocell Announces Participation at the Canaccord Genuity Annual Growth Conference

Perth, Australia; 11th August 2026: Regenerative medicine company Orthocell Limited (ASX: OCC, “Orthocell” or the “Company”) is pleased to participate in the Canaccord Genuity 46th Annual Growth Conference, being held in Boston from 11–13 August 2026.

Orthocell Chairman John Van Der Wielen and Managing Director Paul Anderson will meet with life sciences investors during the conference.

A copy of Orthocell’s Investor Presentation is attached to this announcement.

Investors attending the conference may request a one-on-one meeting with Orthocell through their Canaccord Genuity sales representative.

Release authorised by:
Paul Anderson
Orthocell Ltd CEO and MD

For more information, please contact:

General enquiries

Paul Anderson
Orthocell Limited
CEO and MD
P: +61 8 9360 2888
E: paul.anderson@orthocell.com

Media enquiries

Haley Chartres
H^ACK Director
P: +61 423 139 163
E: haley@hck.digital

Investor enquiries

Shaun Duffy
VECTOR Advisors
P: +61 404 094 384
E: sduffy@vectoradvisors.au

About Orthocell Limited

ACN 118 897 135

Registered Office – Level 2, 161 Campus Drive, Murdoch University, Murdoch WA 6150 Australia

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of bone and soft tissue injuries. Orthocell's portfolio of products include a platform of collagen medical devices which facilitate tissue reconstruction and healing in a variety of dental and orthopaedic reconstructive applications. Striate+™ was the first product approved for dental GBR applications, is cleared for use in the US, Australia, New Zealand, Singapore, UK, Europe, Canada and Brazil and is distributed globally by BioHorizons Implant Systems Inc. Remplir™, for peripheral nerve reconstruction, recently gained clearance for use in the US. The Company has appointed a network of specialist US distributors and recorded initial sales. The Company's flagship nerve repair product is also approved in Australia, New Zealand and Singapore where it is distributed by Device Technologies Group. Other Remplir approvals include Thailand, Canada and Hong Kong. SmrtGraft™, for tendon repair, is available in Australia under Special Access Scheme or participation in a clinical trial. The Company's other major products are autologous cell therapies which aim to regenerate damaged tendon and cartilage tissue. Orthocell is accelerating the development of its tendon cell therapy in the US with technology transfer and FDA engagement to confirm the path to the US market and prepare for partnering discussions.

For more information on Orthocell, please visit www.orthocell.com or follow us on Twitter @OrthocellLtd and LinkedIn www.linkedin.com/company/orthocell-ltd

Forward Looking Statement

Any statements in this press release about future expectations, plans and prospects for the Company, the Company's strategy, future operations, and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the Company's ability to successfully develop its product candidates and timely complete its planned clinical programs and the Company's ability to obtain marketing approvals for its product candidates. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.



Investor Presentation

Canaccord Annual Growth Conference
August 2026



Disclaimer

This presentation, prepared by Orthocell Ltd (“Company”), does not constitute, or form part of, an offer to sell or the solicitation of an offer to subscribe for or buy any securities, nor the solicitation of any vote or approval in any jurisdiction, nor shall there be any sale, issue or transfer of the securities referred to in this presentation in any jurisdiction in contravention of applicable law. Persons needing advice should consult their stockbroker, bank manager, solicitor, accountant or other independent financial advisor.

This document is confidential and has been made available in confidence. It may not be reproduced, disclosed to third parties or made public in any way or used for any purpose other than in connection with the proposed investment opportunity without the express written permission of the Company.

This presentation should not be relied upon as a representation of any matter that an advisor or potential investor should consider in evaluating the Company. The Company and its related bodies corporate or any of its directors, agents, officers or employees do not make any representation or warranty, express or implied, as to the accuracy or completeness of any information, statements or

representations contained in this presentation, and they do not accept any liability whatsoever (including in negligence) for any information, representation or statement made in or omitted from this presentation.

This document contains certain forward-looking statements which involve known and unknown risks, delays and uncertainties not under the Company’s control which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-looking statements. The Company makes no representation or warranty, express or implied, as to or endorsement of the accuracy or completeness of any information, statements or representations contained in this presentation with respect to the Company.

It is acknowledged that the Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances or unanticipated events occurring after the date of this presentation except as required by law or by any appropriate regulatory authority.

Orthocell at a Glance

Australian medical technology company with growing international revenue driven by the commercialisation of its flagship nerve repair product, Remplir™, in the ~US\$2 billion U.S. market¹.



Fully funded and investing in sales growth


\$44 million in cash reserves², no financial debt³ and no royalty liabilities to execute sales growth strategy.



Remplir U.S. strategy on track with continued global expansion

Remplir U.S. key commercial metrics demonstrating strong growth with sales continuing to build.

EU/UK clearance expected 2H CY26.



US\$3.5 billion¹ global nerve repair market

Approved and now selling in AUS, NZL, USA, CAN, SGP, HKG and THA.

Company anticipating a material uplift in U.S. revenue in the upcoming quarters.

1. Referenced papers used to estimate peripheral nerve procedures in the US per annum. Papers used included both the US and OUS databases and studies.
2. AU\$44.1M as of 30 June 2026, this includes \$9.4 million in cash and cash equivalents and \$34.7 million in security and term deposits with maturities ranging from 3 to 12 months.
3. No long-term secured debt facilities. The Company maintains a short-term premium funding facility used to finance insurance premiums, repaid within the policy period.

Corporate Snapshot

Fully funded and investing in growth, supported by leading life science institutional investors.

ASX: OCC Trading Information

Share Price (as @ 06 August 2026) **\$0.75**

12 month low/high \$0.70/\$1.60

Shares outstanding ~272M

Market Capitalisation ~\$205M

Cash (30th June) ~\$44M¹


Debt (30th June) Nil

Substantial Shareholders **%**

Founders & Management ~10%

HNW's & Institutions ~15%

12 Month Share Price And Volume



Strong balance sheet, no debt, no royalties

1. Funds Available of AU\$44.1M as of 30 June 2026, this includes \$9.4 million in cash and cash equivalents and \$34.7 million in security and term deposits with maturities ranging from 3 to 12 months.

Highly Credentialed Board

Orthocell's board, including John Van Der Wielen and Professor Fiona Wood AM, strengthens the Company's ability to scale globally and drive revenue growth.



Mr John Van der Wielen

Independent Non-Executive Chairman

- 35+ years experience in international financial services including large funds management, insurance and private banking
- Former CEO of HBF with annual revenues over \$2B
- Extensive corporate strategy, institutional and strategic investor engagement and M&A transaction experience



Mr Paul Anderson

Founder and Managing Director

- 25+ years in regenerative medicine industry
- Former MD at Verigen, successfully commercialised cartilage repair cell therapy (MACI)
- Extensive experience in product development, navigating regulatory pathways, international market launches, medical education and sales force leadership



Dr Ravi I. Thadhani

Independent Non-Executive Director

- 30 years of specialist experience working in US healthcare sector – highly regarded executive, medical administrator and researcher
- Former professor of medicine at Harvard Medical School and chief academic officer at Mass General Brigham hospital, where he oversaw a \$2.3 billion research enterprise
- Extensive U.S. regulatory experience and commercialisation of devices and therapeutics



Professor Fiona Wood AM

Non-Executive Director

- 30+ years experience as a plastic and reconstructive surgeon
- Inventor of RECELL “spray on skin” treatment, now supplied by Avita Medical Inc, a AU\$450M dual-listed company with operations in 30+ countries including the US
- Unrivalled track record in development and commercialisation of innovative regenerative medicine products.



Mr Michael McNulty

Independent Non-Executive Director

- Commenced 1 September 2025
- Chartered Accountant with 30+ years of accounting and finance experience.
- Former Managing Partner, Deloitte Perth and member of the Deloitte Australia Board.
- Chair Audit Committee.

U.S. Remplir™ - July Commercial Momentum

Commercial momentum continued to build throughout July 2026 for Remplir in the U.S.



Sales

3 new distributors

Signed, widening U.S. coverage

2 hospitals buying direct

For stock replenishment

First GPO national contracts

Signed, opening national hospital purchasing

46 VAC applications approved

As of 31 July



Education

6 abstracts submitted

To U.S. scientific conferences, deepening clinical evidence

7 US KOLs engaged

For the ASSH Innovation Forum and September skills lab

2 training events completed

Florida Ortho Institute Cadaveric Course & ASSH Boot Camp gave fellows and registrars hands-on Remplir experience



Marketing

Expanding hospital usage

Surgeons gaining access to Remplir in multiple hospitals

14 new surgeons

On-boarded in 2 months (June-July)

Online surgeon training portal


Created to support clinical application of Remplir

The Lassonde Curve – Market Valuation Lifecycle

U.S. Market Access Secured, Entering Initial Market Penetration, with Material U.S. Revenue Growth Expected.

RISK HORIZON

- Competition and pricing
- Adoption and execution
- Regulatory and approval
- Clinical and technology



1. Breakeven is cash breakeven and reflects the point at which net operating cash flow is zero, based on current pricing and cost assumptions.

Nerve repair

Remplir™ is engineered with Orthocell's proprietary SMRT™ technology to help patients reclaim touch, movement, and their lives.




Remplir™

made SMRT™



Remplir™ Nerve Repair, made SMRT

Collagen nerve wrap used in the repair of peripheral nerve injuries - reclaiming patients touch, movement and function.



Guiding predictable outcomes in peripheral nerve repair ←



Mimics the natural epineurium with an absolute collagen wrap



Creates an optimal healing environment for nerve regeneration



Easy to handle and suture sparing, simplifying the surgical process




Protects the repair site from scarring, adhesions, and inflammation

Remplir™ Peripheral Nerve Repair Trends

700,000 US Peripheral nerve repair procedures every year. 90% still performed with suturing only.



Suturing success rates can be highly variable ranging from 50 – 70%



Limitations of Suturing

- Technically difficult to achieve alignment and tensionless repair
- Induces foreign body reaction leading to chronic inflammation, fibrosis and scarring
- Can lead to suboptimal axonal regeneration and return of function and sensation

Remplir™ Significant US Market Opportunity

Orthocell has commenced commercial distribution into an estimated US\$2 billion total addressable nerve repair market¹ in the US alone.





Remplir is not seeking to replace a current dominant market incumbent.
Devices are only used in ~10% of procedures.

Current devices are not widely adopted


- Materials are too rigid, challenging to deploy and make it difficult to manage size differences between nerve ends, leading to compression injuries or neuroma formation
- Fail to fully integrate into native tissue, leaving residual material that impairs the healing process
- Have not significantly improved the consistency of outcomes



Current devices



Remplir™



Remplir™ Compelling Clinical Results

Compelling 90% success rate achieved in Remplir nerve repair real world study (RWE).
Data to support continued US sales roll out and EU + UK market launch.



Latest results from the Remplir RWE study demonstrate an overall treatment success rate of **89.7%, based on performance data from 66 patients (78 nerve procedures).**



- Patients were aged 14 to 82 years, with the majority of procedures performed in the upper limb, including decompression and reconstruction of severed nerves (nerve transfer and grafting).
- No post-treatment complications or adverse effects to Remplir were reported, reinforcing its well-established safety profile and high biocompatibility, and strengthening its position as the best-performing nerve wrap in Australia.

Procedure Type	Patients (n)	Nerve Procedures (n)	Treatment Success
Motor nerve reconstruction	19	31	90.3% (28 of 31)
Nerve decompression	47	47	89.4% (42 of 47)
Total	66	78	89.7% (70 of 78)

Strategy and Focus



ortho·cell

Key highlights for the quarter ended 30 June 2026

Establish Orthocell as a global regenerative medicine leader through disciplined growth, operational excellence and a sustainable product pipeline, achieving ASX 300 inclusion.



Strategic
focus

Win in the Americas

Continue growth
in ANZ and Asia

Build global
footprint

Advance the
product pipeline



June Quarter
Operational
Highlights

- Commercialisation of Remplir in the US continues to track ahead of expectations
- Distributor network expanded to 20+ states and ~50% of the U.S. population
- Appointment of a Thai distributor for Remplir, strengthening our Asia-Pacific commercial footprint
- Continued adoption of Remplir in Australia with strong growth for the quarter
- Remplir global humanitarian reach expanded through an initiative delivering Remplir to victims of war in Ukraine
- Remplir UK / EU market access program progressing according to schedule
- Remplir nerve sparing prostate cancer surgery commercial opportunity gathers momentum
- Commencement of U.S. FDA regulatory program for SmrtWrap™ tendon repair application

FY26 Key performance metrics

Record revenue of \$13.2 million for FY26, up 44% on the prior financial year, and \$3.8 million for the June quarter, an increase of 20% on the March quarter, with Q4 FY26 delivering record quarterly revenue and strong performance across all six key metrics, extending a three-year track record of consistent commercial growth.



1. FY26 Revenue

A\$13.2M

⬆ 44% growth YoY



2. Q4 FY26 Revenue

A\$3.8M


⬆ 20% growth QoQ



3. Funds Available¹

A\$44.1M

⬆ 4.6 years cash runway²



4. Q4 FY26 Revenue (Remplir™ U.S.)

A\$0.33M

⬆ 10% growth QoQ



5. Cumulative Hospitals³ (Remplir U.S.)

70

⬆ 27% growth QoQ



6. Cumulative Surgeons³ (Remplir U.S.)

76

⬆ 55% growth QoQ

1. Funds Available of AU\$44.1M as of 30 June 2026, this includes \$9.4 million in cash and cash equivalents and \$34.7 million in security and term deposits with maturities ranging from 3 to 12 months.



2. Cash runway is calculated as Funds Available divided by annualised 4Q 2026 normalised operating cash burn.

3. Cumulative hospitals and surgeons is the total cumulative number of individual hospitals and surgeons that have purchased one or more units of Remplir.

4. Growth percentages are calculated on unrounded figures and may differ slightly from recalculations based on rounded numbers shown.

Quarterly and FY26 revenue growth


U.S. Remplir™ sales continue to grow quarter on quarter, with \$0.33M revenue for Q4 FY26, \$0.92M since launch and Remplir contributing the vast majority of the 44% year-on-year growth for Orthocell



1.Revenue includes product sales, sundry, licensing, grant and interest income (excludes R&D tax refund recorded as income)
2.Excluding US Remplir Sales where applicable.
3.Growth percentages are calculated on unrounded figures and may differ slightly from recalculations based on rounded numbers shown.

Remplir™ AU/NZ Performance since launch¹

Significant growth achieved since launch, with 370 surgeons and 239 hospitals.³



1. Source: Distributor reported sales data since product launch, including quarterly unit volumes.
2. CQGR = compound quarterly growth rate.
3. Actual numbers provided by Device Technologies Australia.

US update

Gaining market access and
growing the customer base of
Remplir™



ortho·cell

Remplir™ significant U.S. market opportunity

We are targeting 10% of the 700,000¹ US Peripheral nerve repair procedures every year, with Orthocell cash breakeven at ~6,000 procedures.

700,000
US Peripheral
nerve repair
procedures
every year.

Targeting 10%, with
an initial focus on
5% of the market

 ~ **60,000**
Devices³

 **35,000**
Procedures

Breakeven²

 ~ **10,000**
Devices³

 ~ **6,000**
Procedures

1. Referenced papers used to estimate peripheral nerve procedures in the US per annum. Papers used included both US and OUS databases and studies.

2. Breakeven is cash breakeven and reflects the point at which net operating cash flow is zero, based on current pricing and cost assumptions.

3. ~1.7 units per procedure, Average units per procedure reflects observed utilisation from available data, supplemented by clinical assumptions regarding standard use per operation.

FY26 U.S. Remplir™ commercialisation performance

Commercialisation of Remplir in the U.S. continues to track ahead of expectations.

Key metrics as at 30 June 2026:



50%

Distributor Coverage
(coverage of U.S. population)

Distributor coverage exceeded targets by 25%, with 18 distributors covering approximately 50% of the U.S. population across 20+ states on the East and West coasts².



70

Cumulative Hospitals¹
(total cumulative)

Hospitals purchasing Remplir reached 70, with over 100 VAC approvals submitted, in process or approved, reflecting strong early adoption.



76

Cumulative Surgeons¹
(total cumulative)


76 surgeons have purchased one or more units of Remplir, supported by strong surgeon feedback, exceeding initial expectations.

1. Cumulative hospitals and surgeons is the total cumulative number of individual hospitals and surgeons that have purchased one or more units of Remplir as at 30 June 2026.
2. As at 30 June, 2026

U.S. Remplir™ commercial momentum is building


Exceptional early growth since the first sale of Remplir on 26 June 2025.

U.S. Remplir Hospitals Cumulative by Quarter¹




Hospitals have grown to 70 in just over a year (26th June, first sale), representing a +189% CQGR² and strong growth in hospital access.

U.S. Remplir Surgeons Cumulative by Quarter¹



Surgeons have grown to 76 in just over a year (26th June, first sale), representing a +195% CQGR² and strong growth in clinical adoption.

U.S. Remplir Unit Sales by Quarter



Unit Sales have grown to 119 per quarter in just a year (26th June, first sale), representing +230% CQGR² and strong sales growth.

1. Number of Hospitals and Surgeons as at 30 June, 2026
2. CQGR = compound quarterly growth rate

FY27 U.S. Remplir™ commercialisation targets

As commercial penetration continues to build, Orthocell is positioned for a material uplift in U.S. revenue.



80%

Distributor Coverage
(coverage of U.S. population)

Work with our distributor partners to increase our state coverage and create more experts in the field. We are targeting 80% distributor coverage of the US population, covering 30+ states.



100-150

Cumulative Hospitals¹
(total cumulative)

Continue to open new accounts through the submission of Value Assessment Committee (VAC) approvals, with a target of 100-150 hospitals with one or more device sales.



150-200

Cumulative Surgeons¹
(total cumulative)

Surgeon on-boarding through education, product demonstration and clinical efficacy, with a target of 150-200 surgeons with one or more device sales.

1. Cumulative hospitals and surgeons is the total cumulative number of individual hospitals and surgeons that have purchased one or more units of Remplir.

Investing to meet future growth

Capacity upgrades in progress to deliver the volumes estimated and reduce the cost of sale.

Stage 1 expansion capital approved

- \$5–5.5M¹ investment to expand the office footprint, increasing manufacturing and warehousing capacity
- Construction beginning in H2CY26 and completion scheduled late 2027

Automation project in the validation phase

- Automated processing and fume-hood upgrades
- No increase to headcount in the medium term
- Enabling 24-hour operations

Secure and reliable supply chain

- Manufacturing upgrades will provide inventory to support expected growth demands
- Inventory availability unaffected during construction with stock held in the US and AU

Designed for scalable production

- Manufacturing cycle times reduced
- Improved device unit operating costs
- Four times the current device manufacturing capacity




1. Includes acquisition of new machines post-automation project completion

Promising New Application for Remplir™ in Prostate Cancer Surgery

Remplir is being used in prostate surgery to preserve nerve function. Nerve-sparing RARP could expand the U.S. TAM from US\$1.6B to ~US\$2B¹. Initial patient data expected 2H CY26.

- Australian urologists are using Remplir in prostate surgery to reduce nerve-related complications.
- Up to 80% of men experience erectile dysfunction and 35% urinary incontinence due to NVB nerve damage post-surgery.
- Used in ~200 Australian surgeries to improve erectile function and continence recovery.
- Procedure data to be released when available. Investing in further research and medical education.
- Prostate cancer is the most diagnosed cancer in men globally — a significant TAM expansion opportunity for Remplir.



¹. Referenced papers used to estimate peripheral nerve procedures in the US per annum. Papers used included both the US and OUS databases and studies

Investment highlights



Best-in-class platform for Bone, Nerve and Tendon repair now selling in nine¹

jurisdictions.
Compelling supportive clinical data.



Product margins retained in-house
manufacturing facility and all IP owned by the company.



Growing international revenues targeting large under penetrated markets.

We have maintained constant growth into new markets with expansion planned into the US\$750 million² EU/UK market following expected approval in 2H CY26 .



Remplir U.S. Strategy is on-track.

Market access activities are clearly defined with execution progressing as planned and sales continuing to build.



Fully funded and investing in sales growth

clear path to cash breakeven requiring less than 1% U.S. market share - while maintaining a cash balance in the high \$20Ms to support execution.

1. Orthocell's collagen platform of products, including Striate+™ and Remplir™.

2. EU and UK nerve repair market sizes estimated using referenced papers from both US and OUS databases and studies.

Achievements and upcoming catalysts¹



Remplir™ | Nerve repair, made SMRT

Foundations in place for U.S. growth	Achieved
Appoint first and second distributors in CAN	Achieved
Appoint exclusive distributor in HKG	Achieved
HK first surgical use	Achieved
EU+UK submissions lodged	Achieved
FY25 R&D tax refund (\$3M)	Achieved
Appoint exclusive distributor in UK	Achieved
First sale in Canada	Achieved
Appoint THA distributor	Achieved
First Thailand sale	Q3 CY26
Initial prostate patient data	2H CY26
EU+UK market clearance	2H CY26
SmrtWrap Tendon US Pre-Submission	2H CY26

1. Timelines may be subject to change due to circumstances not under the Company's control



Authorised for release by
The Board of Directors of Orthocell Limited

P: +61 8 9360 2888
E: paul.anderson@orthocell.com

orthocell.com